As part of our continuing efforts to improve the quality and affordability of health care, we are making important changes to the precertification process for our members who receive alglucerase (Ceredase®), imiglucerase (Cerezyme®), velaglucerase alfa (VPRIV®), or eculizumab (Soliris®). Effective January 1, 2012, all precertification requests for these drugs will be reviewed to determine if members are receiving them in the setting that is cost-effective, safe, and clinically appropriate for their medical needs.
Read more about this change in the December edition of Partners in Health UpdateSM.